Cargando…

Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir

Background: The coronavirus 2019 (COVID-19) disease, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus led to a global pandemic. HCQ and FPV were used early in the pandemic as a treatment modality for COVID-19. Various studies evaluated the HCQ and FPV effectiveness, b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alosaimi, Bandar, Alshanbari, Huda M., Alturaiqy, Muath, AlRawi, Halah Z., Alamri, Saad, Albujaidy, Asma, Bin Sabaan, Aljawharah, Alrashed, Ahmed A., Alamer, Ahmad, Alghofaili, Fayez, Al-Duraymih, Khaled, Alshalani, Abdulaziz J., Alturaiki, Wael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785070/ https://www.ncbi.nlm.nih.gov/pubmed/36558907 http://dx.doi.org/10.3390/ph15121456

Ejemplares similares

Prediction and Classification of COVID-19 Admissions to Intensive Care Units (ICU) Using Weighted Radial Kernel SVM Coupled with Recursive Feature Elimination (RFE)
por: Alshanbari, Huda M., et al.
Publicado: (2022)

Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir
por: Guner, Rahmet, et al.
Publicado: (2021)

Confusion and Hallucination: A Case Report of an Unusual Presentation of COVID-19
por: Aljumaiah, Rawabi, et al.
Publicado: (2021)

Azithromycin/favipiravir/hydroxychloroquine: Various toxicities: 7 case reports
Publicado: (2022)

Complement Anaphylatoxins and Inflammatory Cytokines as Prognostic Markers for COVID-19 Severity and In-Hospital Mortality
por: Alosaimi, Bandar, et al.
Publicado: (2021)

SARS-CoV-2: An Overview of Virus Genetics, Transmission, and Immunopathogenesis
por: Farrag, Mohamed A., et al.
Publicado: (2021)

Azithromycin/favipiravir/hydroxychloroquine: Hypoglycaemia and off label use: case report
Publicado: (2021)

Interaction between favipiravir and hydroxychloroquine and their combined drug assessment: in silico investigations
por: Parlak, Cemal, et al.
Publicado: (2021)

Cost-effectiveness of Favipiravir in moderately to severely ill COVID-19 patients in the real-world setting of Saudi arabian pandemic referral hospitals()
por: Alamer, Ahmad, et al.
Publicado: (2023)

Azithromycin/favipiravir/hydroxychloroquine: Lack of efficacy and off-label use: case report
Publicado: (2021)

Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease
por: AlQahtani, Manaf, et al.
Publicado: (2022)

Azithromycin/favipiravir/hydroxychloroquine: Ventricular tachycardia and off-label use: 2 case reports
Publicado: (2020)

Effectiveness and Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19: A Retrospective Study
por: Alotaibi, Musim, et al.
Publicado: (2021)

Favipiravir/hydroxychloroquine/methylprednisolone: Nephrotoxicity following an off-label use: 2 case reports
Publicado: (2021)

The effect of favipiravir versus hydroxychloroquine on clinical and laboratory findings in COVID-19 in healthcare workers
por: Turan, Derya Bayırlı, et al.
Publicado: (2022)

Elevated Expression Levels of Lung Complement Anaphylatoxin, Neutrophil Chemoattractant Chemokine IL-8, and RANTES in MERS-CoV-Infected Patients: Predictive Biomarkers for Disease Severity and Mortality
por: Hamed, Maaweya E., et al.
Publicado: (2021)

Saudi English: A Descriptive Analysis of English Language Variations in Saudi Arabia
por: AlRawi, Maather, et al.
Publicado: (2022)

Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial
por: Bosaeed, Mohammad, et al.
Publicado: (2021)

Favipiravir/hydroxychloroquine/oseltamivir: Tonic clonic seizures following off label use: case report
Publicado: (2020)

Author Correction: Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease
por: AlQahtani, Manaf, et al.
Publicado: (2022)

Cardiovascular complications and outcomes among athletes with COVID-19 disease: a systematic review
por: Alosaimi, Bandar, et al.
Publicado: (2022)

EFFECTS OF HYDROXYCHLOROQUINE PLUS FAVIPIRAVIR TREATMENT ON THE CLINICAL COURSE AND BIOMARKERS IN HOSPITALIZED COVID-19 PATIENTS WITH PNEUMONIA
por: Delen, Leman Acun, et al.
Publicado: (2022)

RETRACTED ARTICLE: Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial
por: Dabbous, Hany M., et al.
Publicado: (2021)

Retraction Note: Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial
por: Dabbous, Hany M., et al.
Publicado: (2021)

Association between the expression of toll-like receptors, cytokines, and homeostatic chemokines in SARS-CoV-2 infection and COVID-19 severity
por: Alturaiki, Wael, et al.
Publicado: (2022)

Oral Health and Patterns of Dental Visits Among Diabetic Patients in the Eastern Province of Saudi Arabia
por: AlTuraiki, Ahmad Mohammed, et al.
Publicado: (2021)

Favipiravir Effectiveness and Safety in Hospitalized Moderate-Severe COVID-19 Patients: Observational Prospective Multicenter Investigation in Saudi Arabia
por: Al-Muhsen, Saleh, et al.
Publicado: (2022)

Traditional Arabic & Islamic medicine: validation and empirical assessment of a conceptual model in Qatar
por: AlRawi, Sara N., et al.
Publicado: (2017)

Tocilizumab for treating severe COVID‐19 pneumonia refractory to combined hydroxychloroquine, lopinavir plus ritonavir, and favipiravir: A case series
por: Surabotsophon, Manoon, et al.
Publicado: (2020)

Moderately Low Effectiveness of the Influenza Quadrivalent Vaccine: Potential Mismatch between Circulating Strains and Vaccine Strains
por: Awadalla, Maaweya E., et al.
Publicado: (2023)

Increased Prevalence of EBV Infection in Nasopharyngeal Carcinoma Patients: A Six-Year Cross-Sectional Study
por: Al-Anazi, Abdullah E., et al.
Publicado: (2023)

Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity
por: Kaptein, Suzanne J. F., et al.
Publicado: (2020)

A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial
por: Bosaeed, Mohammad, et al.
Publicado: (2020)

Challenges of measuring accurate estradiol levels in aromatase inhibitor‐treated postmenopausal breast cancer patients on vaginal estrogen therapy
por: Niravath, Polly, et al.
Publicado: (2017)

The Role of Three-dimensional Printed Models in Women’s Health
por: AlRawi, Afnan, et al.
Publicado: (2023)

ICU admission and favipiravir
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Outpatients in Saudi Arabia
por: Mohana, Abdulrhman, et al.
Publicado: (2021)

A Rare Case and Presentation of Traumatic Penetrating Aortic Arch Injury: A Case Report and Literature Review
por: AlAli, Mohammed N, et al.
Publicado: (2022)

Overweight and obesity among Saudi children and adolescents: Where do we stand today?
por: Al-Hussaini, Abdulrahman, et al.
Publicado: (2019)

Azithromycin/favipiravir/hydroxychloroquine interactions: Corrected QT (QTc) interval prolongation due to pharmacodynamic interaction following off label use: 2 case reports
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hkd5jpq2rdh312m5c3pulqghu9